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The early results of the CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction
study were recently published in the Lancet.1 This study is a phase 1 prospective randomised study,
performed at two centres. The study was designed to test the hypothesis that intracoronary infusion of
autologous cardiac-derived cells following myocardial infarction can reduce the size of the infarct and
increase the amount of viable myocardium. The eligible patients were randomised in a 2:1 ratio to
receive CDCs or standard care. In all, 17 patients were randomised to cell therapy and 8 to standard
care. The cell therapy consisted of an infusion of 25 million cells into the infarct related artery, 1.5–3
months after successful primary angioplasty in patients who developed LV dysfunction (EF less than
37 per cent). The cells were derived from RV endomyocardial biopsies performed within the previous
37 days. The number of cells was determined from previous experimental studies of the maximum
number of cells which can be injected without inducing infarction. The study was not blinded because
of ethical considerations regarding performing right ventricular biopsy on the controls. The exclusion
criteria included patients who had evidence of right ventricular infarction, or could not have an MRI
examination because of claustrophobia or prior insertion of devices. There was no death, myocardial
infarction or serious arrhythmia reported in either group during the period of follow up, which was
between 6–12 months. Serious adverse events were observed in 24 percent of the intervention group
versus 12 per cent in the controls (p not significant).
Although the study was not powered to determine efficacy, the authors observed significant
reduction in the size of the infarct (27.7 per cent at 6 month and 212.3 per cent at 12 months) and
importantly an increase in the amount of viable myocardium. In addition there was a significant
increase in the thickness and rate of thickening in the peri-infarction zone, however there was no
change in ejection fraction of left ventricular volumes.
The authors concluded that injection of a specific number of CDCs into the infarct related artery is
safe and should be tried further.
The strong points in this trial are the fact that it has shown for the first time that injection of CDCs
in humans is feasible and safe, and that this might increase the amount of viable myocardium and
therefore influence longer-term outcome. The study was started after extensive preclinical research by
the authors, to justify moving into the clinic. In addition the choice of MRI to assess results enhances
the ultimate value of the study.
Cite this article as: Yacoub MH, Terrovitis J. CADUCEUS, SCIPIO, ALCADIA: Cell therapy trials using
cardiac-derived cells for patients with post myocardial infarction LV dysfunction, still evolving,
Global Cardiology Science & Practice 2013:3 http://dx.doi.org/10.5339/gcsp.2013.3
http://dx.doi.org/
10.5339/gcsp.2013.3
Submitted: 12 December 2012
Accepted: 19 February 2013
q 2013 Yacoub, Terrovitis, licensee
Bloomsbury Qatar Foundation
Journals. This is an open access
article distributed under the terms of
the Creative Commons Attribution
license CC BY 3.0, which permits
unrestricted use, distribution and
reproduction in any medium,
provided the original work is
properly cited.
1Qatar Cardiovascular Research Center,
Doha, Qatar
2University of Athens School of
Medicine, Athens, Greece
*Email: john.terrovitis@gmail.com
What have we learned?
In spite of the fact that the results of the study are potentially very exciting, they are not sufficient to
influence practice, because of the small number of patients, the short period of follow up, the putative
nature of the results, and the limit imposed on the number of cells which can be safely injected into the
coronary arteries because of the large size of the CDCs (20 microns in diameter) which is considerably
larger than the myocardial capillaries (7 microns).
In addition, although the CDCs are cardiac derived and have been labelled progenitor cells, there is
no evidence that they can differentiate into myocardial cells, and therefore the mechanisms involved in
the beneficial actions observed remain unknown. Recent studies using carbon-14 or multi-isotope
imaging mass spectrometry (MIMS), suggest that myocardial regeneration following injury results from
division of mature myocardial cells. Future reports about the longer term results from the same group in
phase 2 trials are awaited with great interest, while other strategies to enhance division of adult
cardiomyocytes2–6 should be actively explored.
SCIPIO
The early results of the phase 1 trial, cardiac Stem Cell In Patients with Ischemic cardiomyopathy
(SCIPIO) were recently published in The Lancet.7 This trial appears to have raised expectations to an
unrealistic degree with the hope that “it will transform cardiac cell therapy that its namesake, Scipio
Africanus achieved in Roman Military Campaigns”.8 The trial is an open label randomised trial of
patients with post infarction left ventricular dysfunction (EF less than 45 per cent) requiring surgical
revascularisation. At the time of operation, performed at one of two centres in Kentucky, the atrial
appendage was excised and sent to Dr Piero Anversa’s lab in Boston. Following cell culture, cells
expressing the cell surface marker c-kit, which are also lineage negative, were extracted using magnetic
beads and thoroughly characterised and tested for lack of senility and ability to proliferate. The cells
were then shipped to another lab in Kentucky to be prepared for clinical use. For the patients
randomised to the cell therapy arm, intra-coronary injection of the specified number of cells were
injected into the graft or vessel supplying the infarction area about 120 days after operation. For
patients with large anterior infarcts, one million cells were injected, while for patients with smaller
posterior infarcts one or more injections of 500,000 cells were used. The primary end point was
short-term safety and the secondary end point was efficacy as determined by clinical, quality of life
questionnaire and MRI at 1 and 4 months. Patient recruitment utilised a complex system with the first
nine consecutive eligible patients assigned to cell therapy and the next four conseutivec patients
acting as controls. After that patients were randomised in a 3:2 ratio to treatment and controls. In all,
16 patients received cells and 7 were controls.
The authors report no mortality or major adverse events following this form of therapy. In addition,
although the study was not powered to address efficacy, in the patients who could be investigated by
MRI, there was improvement in EF by 8 and 12 percent at one and four-year time points in the cell
therapy group, as opposed to no improvement in the controls. There was also evidence of diminution in
the size of the infarct in the cell therapy group. These results are superior to those described after
infusion of bone marrow derived cells. However the numbers are small, and the potential confounding
effect of myocardial revascularisation cannot be excluded.
What have we learned?
The results of this phase 1 trial are unlikely to influence practice because of the putative nature of the
findings and the small number of patients. The results of the phase 2 trial will be eagerly awaited.
Similarly, studies to define the mechanism of changes observed would be of great value. In the
meantime, the major expectations have to wait (Figure 1).
ALCADIA
Results of the ALCADIA (AutoLogous Human CArdiac-Derived Stem Cell To Treat Ischemic
cArdiomyopathy) trial were presented during the American Heart Association Scientific Sessions in
November 2012.9 The study evaluated a hybrid cell therapy application, namely the administration of
autologous cardiac stem cells together with a controlled release formulation of basic Fibroblast Growth
Factor (bFGF) in patients with ischemic cardiomyopathy and heart failure.
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This is one of the first human trials, together with CADUCEUS and SCIPIO, where cardiac derived cells
are used to treat heart failure. ALCADIA is the smallest and most preliminary of them and the final
results have not been published yet.
ALCADIA was an open label, non-randomized, phase 1 safety/feasibility study of autologous cardiac
derived stem cell combined with bFGF administration in advanced heart failure.9 Six patients
(55.5 ^ 10.8 years old, 5 men and one woman) with ischemic cardiomyopathy (left ventricular ejection
fraction between 15 and 45%), symptomatic heart failure (NYHA class III or IV), myocardial viability and
indication for coronary artery bypass surgery, were enrolled.
Cardiac-derived stem cells were grown from endomyocardial biopsies and expanded for a period of
approximately one month. They were delivered to the heart during the subsequent CABG surgery, by
20 intramyocardial injections (total number 0.5million/kg). Finally, a biodegradable gelatin hydrogel
sheet containing 200mg of bFGF was implanted on the epicardium, covering the injection sites areas.
The primary safety end point was the occurrence of Major Cardiac Event (MACE) during the one year
follow up period. Efficacy end points included changes in Left Ventricular Ejection Fraction (LVEF,
assessed by echocardiography and MRI), infarct volume (assessed by MRI) and symptoms (NYHA class
and exercise capacity) at 6 months.
One patient experienced acute occlusion of a graft 3 weeks after surgery and was excluded from
further evaluation. From the remaining five patients, one experienced a worsening heart failure episode
during the follow up. No other serious adverse events were observed. At 6 months, there was an
increase in LVEF measured by both imaging modalities (9% and 12%, by echocardiography and MRI
respectively). Infarct size decreased by 3.3% of the total LV volume and maximal aerobic exercise
capacity (VO2peak) increased by 4.5ml/kg/min.
What have we learned?
The ALCADIA trial is a small, preliminary Phase 1 study without a control group. No conclusions about
the efficacy of this hybrid therapy can be derived. The favorable trends observed in LV function and
symptom severity can also be attributed to the effects of revascularization. In the small number of
patients (five) who were followed for 12 months, there was only one serious adverse event, related to
worsening heart failure; therefore, no concerns about safety were raised.
The concept is interesting since poor cell survival is currently one of the major hurdles limiting the
effectiveness of cell therapies, irrespective of the type of the cell used. Tissue engineering approaches
may offer a solution to this problem. In this study, a sustained release bFGF gelatin hydrogel sheet was
used, in order to augment the effect exerted by the cells. The investigators have previously shown the
efficacy of this method in a preclinical animal model.10 FGF has many attractive properties, since it
Figure 1. Scipio Africanus The Elder was a general in the Second Punic War and statesman of the Roman Republic.
He was best known for defeating Hannibal at the final battle of the Second Punic War at Zama, a feat that earned
him the agnomenAfricanus, the nickname “the Roman Hannibal”, as well as recognition as one of the finest
commanders in military history. Picture credit: http://upload.wikimedia.org/wikipedia/commons/3/38/Scipio
_Africanus_the_Elder.jpg
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promotes cell proliferation and angiogenesis. The cardiac derived cells used in ALCADIA were
autologous and were grown from endomyocardial biopsies. The cells have surface markers
characteristic of mesenchymal cells (CD105 and CD90), but also express transcription factors
characteristic of progenitor cells. It should be noted however that there is no compelling evidence that
these cells can differentiate into cardiomyocytes in vivo and most experimental studies suggest a
paracrine mechanism of action, leading to augmentation of endogenous repair mechanisms (both
cardiomyocyte proliferation and recruitment of resident cardiac stem cells).11
In conclusion, the ALCADIA trial has demonstrated the safety of the combined administration of
autologous cardiac derived stem cells together with a sustained bFGF gelatin hydrogel in patients with
ischemic cardiomyopathy. Larger, prospective, randomized, placebo control clinical trials are required
in order to investigate the effectiveness of this approach.
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